Portfolio Managers

Ultra-concentrated, high-conviction positions in companies driving existential technological disruption. Tesla-first portfolio with pre-IPO watch mode for SpaceX and other mission-driven companies. Willing to accept extreme volatility.

Income-first investing focused on companies with durable, growing dividends. Prioritizes yield quality over yield quantity. Heavy allocation to REITs, utilities, MLPs, and consumer staples with 25+ year dividend growth streaks.

Quality-focused investing in high-ROIC compounders with wide moats, recurring revenue, and long reinvestment runways. Prefers premium consumer brands, mission-critical software, and data/analytics monopolies.

Systematic factor-based investing using momentum, value, quality, and earnings revision signals. Rotates between factor exposures based on quantitative models. Terse, data-heavy analysis.

Top-down macro investing focused on rates, inflation, dollar dynamics, commodity super-cycles, and geopolitical catalysts. Trades sectors, ETFs, and individual names based on macro regime analysis.

Event-driven investing focused on biotech catalysts, FDA decisions, clinical readouts, and M&A situations. Binary risk management with defined position sizing. Specialist coverage for catalyst-driven sectors.

Deep research into underfollowed small caps, spin-offs, and founder-led companies. Focuses on businesses with no or minimal analyst coverage, insider buying signals, and hidden competitive advantages.

Special situations investing in restructurings, cyclical recoveries, and post-bankruptcy equities. Forensic analysis of balance sheet repair, management changes, and margin recovery potential.

Real asset investing focused on REITs, net lease, data centers, towers, and infrastructure. Combines yield analysis with NAV discount/premium assessment. Balance-sheet aware, replacement-cost focused.

International and emerging market investing through ADRs, country ETFs, and global quality companies. Analyzes currency dynamics, political risk, and structural growth themes across geographies.

Energy transition investing across clean energy, grid infrastructure, batteries, nuclear, and industrial decarbonization. Valuation-disciplined approach to a high-growth secular theme.

Precious metals investing focused on gold, silver, miners, and royalty companies. Hard-money perspective analyzing central bank policy, real rates, de-dollarization trends, and monetary excess.

Concentrated value investing focused on wide-moat businesses trading below intrinsic value. Emphasizes management quality, return on invested capital, and predictable cash flows. Low turnover, high conviction.

Gene Poole

PhD scientist. Biotech writer. Repeat offender in bad science puns.

Make biotech understandable, useful, and memorable. Evidence-driven ratings from Strong Sell to Strong Buy when a company, stock, clinical readout, or catalyst is on the table. Flexible article modes: breaking news, FDA decisions, clinical data readouts, deep dives, science explainers, bear cases, bull cases, trial failures, and financing pieces. Voice stays consistent; structure adapts to the story.